Clinical trials: Neuroendocrine Tumor Grade 3
Neuroendocrine (NE) Tumors, Neuroendocrine Tumor GEP Grade 1-3
Life Following Excision of Neuroendocrine Tumors
Neuroendocrine tumors (NETs), often seen as "chronic cancer" present a survival paradox with relatively prolonged patient survival despite active disease.
- Trial name
- LIFENETS (NCT06981455)
- Where
- Canada
- Volunteers
- 246 people
- Sponsor
- Sunnybrook Health Sciences Centre
Cachexia, Lymphoma
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
RATIONALE: Celecoxib may help relieve moderate or severe pain associated with cancer. It may also decrease weight loss and improve muscle strength in cancer patients.
- Conditions
- Cachexia, Lymphoma, Melanoma (Skin), Ovarian Cancer
- Trial name
- NCT00093678
- Testing
- celecoxib, anticachectic therapy, nutritional support
- Sponsor
- Eastern Cooperative Oncology Group
Neuroendocrine Tumor Grade 3
Surufatinib in G3 Neuroendocrine Tumors
The goal of this observational study is to learn about surufatinib in Refractory Metastatic G3 Neuroendocrine Tumors. The main questions it aims to answer are: To evaluate the efficacy and safety of surufatinib in the treatment…
- Trial name
- NCT05973968
- Testing
- Surufatinib
- Volunteers
- 32 people
- Sponsor
- Qilu Hospital of Shandong University
Neuroendocrine Tumors
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in…
- Trial name
- COMPOSE (NCT04919226)
- Testing
- 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 259 people
- Sponsor
- ITM Solucin GmbH
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors…
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor
- Trial name
- NCT01088763
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 12 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Neoplasia's (NENs), Neuroendocrine Tumor GEP Grade 1-3
PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
Neuroendocrine tumours (NETs), better defined as neoplasms (NENs), are a heterogeneous group of neoplasms that range from well-differentiated tumours to more aggressive carcinomas.
- Conditions
- Neuroendocrine Neoplasia's (NENs), Neuroendocrine Tumor GEP Grade 1-3, Neuroendocrine Gastroenteropancreatic Tumour
- Trial name
- PReCedeNT (NCT07185672)
- Testing
- Peptide Receptor Radionuclide Therapy with Lu177 DOTATATE, Capecitabine plus temozolamide
- Where
- 2 sites in India
- Volunteers
- 162 people
- Sponsor
- Tata Memorial Hospital
Schwannomatosis, Pain
Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
The primary objective of this study is to determine whether the administration of tanezumab, an anti-nerve growth factor (NGF) antibody, improves pain relief in schwannomatosis patients receiving background non-NSAID therapy.
- Trial name
- NCT04163419
- Testing
- Tanezumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
Neuroendocrine Carcinoma
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
there is a need for improving chemotherapy regimen for metastatic G3 NEC of GEP and Unknown origin and this goal may be achieved through more "personalized" chemotherapy regimen.the hypothesis is that mFOLFIRINOX regimen could be…
- Trial name
- FOLFIRINEC (NCT04325425)
- Testing
- FOLFOXIRI Protocol, Cisplatin injection
- Where
- 6 sites in France
- Volunteers
- 218 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Grade I Neuroendocrine Carcinoma, Grade II Neuroendocrine Carcinoma
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
This phase II trial studies how well nivolumab and temozolomide work in treating patients with small-cell lung cancer that has come back or does not respond to treatment, or neuroendocrine cancer that has spread to other places…
- Conditions
- Grade I Neuroendocrine Carcinoma, Grade II Neuroendocrine Carcinoma, Grade III Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma
- Trial name
- NCT03728361
- Testing
- Nivolumab, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Dwight Owen